NEW YORK, April 29 (GenomeWeb News) - Sirna Therapeutics reported decreased revenues and widening losses for the first quarter on Tuesday.
Revenues for the quarter totaled $318,000, down from $490,000 for the year-ago period.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Wall Street Journal speaks with patients affected by questionable test results from Theranos.
Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.
Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.
In Science this week: convergent evolution in bird hemoglobin, and more.